Seattle, WA | December 19, 2013

As IDRI’s 20th year comes to a productive close with diagnostics on the market, vaccines in clinical trials, and drugs being discovered for the world’s most devastating infectious diseases, the organization today announced leadership plans for the future.

On Jan. 1, 2014, Stewart Parker, IDRI CEO, will transition into a new role as Senior Advisor to IDRI, while maintaining her seat on IDRI’s Board of Directors. Parker, a well-known figure in Seattle’s biotech community, having served as CEO of Targeted Genetics, joined IDRI in March 2011 to spearhead a three-year plan to develop resources – financial, human and physical – to support IDRI’s scientific efforts.

Parker led efforts to move IDRI into new state-of-the-art headquarters in Seattle’s South Lake Union global health hub in May 2013, while establishing new organizational functions – from development to communications – to increase awareness of IDRI and strengthen functions already in place, including finance and operations. In her new role as Senior Advisor to IDRI, Parker will focus on raising visibility and funding for IDRI.

“I joined IDRI because I believe in this organization’s comprehensive approach to developing new solutions to meet the most critical global health needs,” said Parker. “And, as I step into a different role for the organization and continue serving on the board, I look forward to finding new ways to contribute to fulfilling IDRI’s unique mission.”

Erik Iverson, who currently serves as IDRI’s Executive Vice President of Business Development and External Relations, has been promoted to President, Business and Operations. Prior to joining IDRI in 2011, Iverson served as Associate General Counsel at the Bill & Melinda Gates Foundation. At the Gates Foundation, he was the second attorney on staff, worked for over seven years within the foundation’s Global Health Program, and led the development and implementation of the foundation’s Global Access policy.

“I was motivated to join IDRI because of its world-class technologies and efforts that are vitally important to improving global health, as well as its outstanding scientific and leadership teams,” said Iverson. “I am sincerely proud to have been asked to serve in this role as we move into a new era of opportunities to raise awareness and establish global initiatives for IDRI.”

Iverson will work with IDRI Founder, President and Chief Scientific Officer Steven G. Reed, Ph.D., to lead IDRI’s scientific and business efforts. Reed founded IDRI in 1993 in order to apply advances in immunology and molecular biology to the development of novel diagnostics, vaccines and therapeutic products that could transform the lives of the millions of people at risk for infectious diseases throughout the developing world. Under Reed’s leadership, IDRI has grown to an organization with more than 125 employees and collaborations with nearly 100 organizations around the world.

In 2014, to best position IDRI in executing on its expanding opportunities and efforts, the organization will identify additional scientific leadership to apply IDRI’s technologies and scientific capabilities to a breadth of global health areas. The expanded scientific leadership will allow Reed to increase his focus on identifying and fostering global strategic alliances.

“Over the past 20 years, IDRI has significantly expanded its reach globally, with our technologies and expertise attracting interest from a wide range of organizations and countries around the world,” said Reed. “In addition to the growing number of multinational collaborations, IDRI is establishing an operating presence in a number of developing countries. All of these efforts, and the evolution of IDRI as an organization, are aimed at accomplishing our global health mission.”

About IDRI

As a non-profit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. IDRI combines passion for improving human health with the understanding that it is not just what our scientists know about disease, but what we do to change its course that will have the greatest impact. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit


IDRI: Lee Schoentrup | 206.858.6064 |